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Objectives
 Review NIOSH listed hazardous drugs (HDs) requiring handling 
precautions in hospital and community settings
 Discuss the importance and highlight proper handling and 
disposal of hazardous chemotherapy as outlined in USP <800>
 Review counseling points for precautions and handling of oral 
chemotherapy agents at home
Pre-Assessment Questions
 True or False
 Patients on oral chemotherapy do not need to wear gloves 
during administration
 True or False
 Oral chemotherapy is safe to dispose in the everyday 
trash, as long as it is in its original container
 True or False
 Precautions during every day handling are to protect the 
hazardous drug, not the user
What is a Hazardous Drug (HD)?
 Term first used by ASHP in 1990
 National Institute for Occupational Safety and Health 
(NIOSH) definition:
 Any drug (or active pharmaceutical ingredient) that is 
identified as having ≥ 1 of the following: 
• Carcinogenicity
• Teratogenicity (or developmental toxicity)
• Reproductive toxicity in humans
• Organ toxicity (at low doses in humans or animals)
• Genotoxicity
• Drug that mimics an existing hazardous drug in 
structure or toxicity
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016
Why do we care about HDs?
 ~8 million US healthcare workers are potentially 
exposed to HDs
 Contamination can occur during transport, compounding, 
cleaning and administration
 May lead to absorption by healthcare workers
 Consider HD use at home causing contamination
 Oral chemotherapy
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016
Types of Exposure




NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016
Patient Care Areas
 Contamination also extends beyond the pharmacy 
and into patient care areas
 Not only patients in these areas
 Avoiding surface contamination 
 Surface contamination has been definitively linked to hand 
contamination
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016












NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016
Who is at risk?
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016
USP <800> Inforgraphic
The Evolution of Safe Handling
Clin J Oncol Nurse. 2015; 20(4):377-384




 HDs are categorized into three groups:
 Group 1: Antineoplastic drugs
 Group 2: Non-antineoplastic drugs
 Group 3: Reproductive risk
 NIOSH notes that many drugs in group 1 and 2 also 
carry reproductive risk
 Document provides guidance for personal protective 
equipment (PPE) and ventilated engineering controls 
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016
NIOSH HD List
 Drugs with safe-handling guidelines from the 
manufacturer are automatically put on the list
 NIOSH internal committee performs an initial review 
of all new FDA drug approvals and new warnings on 
existing drugs for a 2-year period
 This is followed by an expert panel that reviews the 
proposals (additions or deletions)




 Each organization should create its own list of drugs 
considered to be hazardous, based on drugs in its 
formulary
 Primarily because reliance on lists of HDs provided 
by NIOSH quickly becomes outdated
 If you use a drug that is not included in the list, check the 
available literature to see whether the unlisted drug 
should be treated as a HD 
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016
Handling and Disposal in 
Healthcare settings
United States Pharmacopeia (USP)
 USP is the only independent, not-for-profit, 
nongovernmental pharmacopeia in the world
 Develop and revise standards
• Standards are enforceable by the FDA and state boards 
of pharmacy
• Identity, strength, quality and purity
 Medicines
 Food ingredients
 Dietary supplements 
https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare
United States Pharmacopeia (USP)






• HD handling in healthcare settings
 USP <825>  
• Compounding radiopharmaceutical drugs 
 Revisions for <795> and <797> have been released 
USP <800>
 Describes the practice & quality standards for 
handling HDs
 Philosophy: no acceptable level of exposure to HDs
 Purpose is to promote the protection of:
• Patients
• Healthcare worker safety
• Environment
 Applies to all healthcare personnel who handle HDs 
and all entities that store, prepare, transport, or 
administer them
 Introduces element of containment
USP Compounding Expert Committee. USP General Chapter <800>
USP <800>
 Management of HDs must include:
 A list of HDs
 Facility and engineering controls
 Competent personnel
 Safe work practices
 Proper use of personal protective equipment (PPE)
 Policies for HD waste segregation and disposal
USP Compounding Expert Committee. USP General Chapter <800>
Maintain a HD List
 Must use NIOSH list as a basis
 Agents on the NIOSH list that must follow USP <800>
 HD active pharmaceutical ingredients
 All antineoplastics that require manipulation
 Other agents on the NIOSH list
 Perform risk assessment
 If no risk assessment performed, must handle as 
hazardous and according to USP <800> requirements
 Entity must review their list at least every 12 months
USP Compounding Expert Committee. USP General Chapter <800>
Assessment of Risk 
 Consider the following:
 Category of HD based on NIOSH
 Dosage form
 Risk of exposure
 Packaging
 Any manipulation that might be required
 Examples of assessments of risk can be found online
 National Community Pharmacy Association
USP Compounding Expert Committee. USP General Chapter <800>
P Kienle and K Douglas. Perform an assessment of risk to comply with USP <800> 
Facilities
 Restrict access to areas where HDs are handled
 Protects persons not involved in HD handling
 Designated areas must be available for:
 Receipt and unpacking
 Storage of HDs
 Nonsterile HD compounding (if performed by the entity)
 Sterile HD compounding (if performed by the entity)
 Also use dedicated equipment
 Ex: designated counting tray for HDs
USP Compounding Expert Committee. USP General Chapter <800>
Receipt & Storage
 Antineoplastic HDs and all HD APIs must be 
unpacked in an area that is neutral/normal or 
negative pressure
 Do not unpack in sterile compounding areas or in positive 
pressure areas
 HDs and APIs requiring manipulation must be stored 
separately from non hazardous medications in an 
externally ventilated, negative-pressure room with at 
least 12 air changes per hour (ACPH)
USP Compounding Expert Committee. USP General Chapter <800>
Engineering Controls
 Required to protect the preparation from cross-
contamination and microbial contamination (if 
sterile compounding)




USP Compounding Expert Committee. USP General Chapter <800>
Engineering Controls
 Containment primary engineering control (C-PEC)
 Ventilated device designed to minimize worker and 
environmental HD exposure
 Required:
• Class II Biological Safety Cabinets (BSC)  
 OR
• Compounding Aseptic Containment Isolator (CACI)




 Compounding aseptic containment isolator (CACI)
https://www.nuaire.com/how-class-two-bsc-work
Engineering Controls
 Containment secondary engineering control (C-SEC)
 The room in which the C-PEC is placed, which must:
• Be externally vented
• Be physically separated (i.e., a different room from 
other preparation areas)
• Have an appropriate air exchange (e.g., ACPH)
• Have a negative pressure
USP Compounding Expert Committee. USP General Chapter <800>
Engineering Controls
 Supplemental engineering controls
 Closed system transfer devices (CSTD)
• MUST be used when administering antineoplastic HDs 
when the dosage form allows
 Not mandated for use in compounding
• CSTDs known to be physically or chemically 
incompatible with a specific HD must not be used for 
that HD
USP Compounding Expert Committee. USP General Chapter <800>
Personal Protective Equipment (PPE)
 Provides worker protection to reduce exposure to 
hazardous drug (HD) aerosols and residues





 Compounding (sterile & nonsterile)
 Administration
 Deactivation/decontamination, cleaning and disinfecting
 Spill control
 Waste disposal
USP Compounding Expert Committee. USP General Chapter <800>
Chemotherapy Gloves
 Must meet American Society for Testing and Materials 
(ASTM) standard D6978
 Should be worn when handling all HDs
 Including non-antineoplastics & for reproductive risk HDs
 Must be powder free
 Inspect prior to use
 When used for sterile compounding, outer gloves 
must be sterile
 Should be changed every 30 minutes unless otherwise 
recommended by the manufacturer
USP Compounding Expert Committee. USP General Chapter <800>
Chemotherapy Gloves
Chemotherapy Gowns
 Must be disposable and shown to resist permeability
 Must close in the back, be long sleeved, and have 
closed cuffs that are elastic or knit
 Lab coats, scrubs or other absorbent materials are 
not appropriate
 Potentially contaminated clothing must not be taken 
home under any circumstance
USP Compounding Expert Committee. USP General Chapter <800>
Head, Hair, Shoe and Sleeve Covers
 Provide protection from contact with HD residue
 When compounding HDs, a 2nd pair of show covers 
must be donned before entering the cleanroom and 
doffed when exiting
 Shoe covers worn in HD handling areas must not be 
worn to other areas
USP Compounding Expert Committee. USP General Chapter <800>
Eye and Face Protection
 Appropriate eye and face protection must be worn 
when there is a risk for spills or splashes of HD
 Administration in the surgical suite or cleaning a spill
 Goggles & face shields
USP Compounding Expert Committee. USP General Chapter <800>
Personal Protective Equipment (PPE)
Disposal of Used PPE
 Consider all PPE worn when handling HDs 
contaminated
 Place them in appropriate waste container per local, 
state, and federal regulations
USP Compounding Expert Committee. USP General Chapter <800>
Personal Protective Equipment
USP Compounding Expert Committee. USP General Chapter <800>
Smith A. USP <800> What you need to know. Illinois Pharmacy Association
Disposal
 All personnel who perform routine custodial waste 
removal/cleaning activities in HD handling areas
 Must be trained in appropriate procedures!
• To protect themselves and the environment 
 Disposal of all HD waste (including unused HDs and 
trace-contaminated PPE) must comply with all 
applicable federal, state, and local regulations




 Must establish written procedures for 
decontamination, deactivation and cleaning
 For sterile compounding, also disinfection
 Must wear appropriate PPE
 2 pairs of gloves and impermeable disposable gowns
 Wet wipe approach
USP Compounding Expert Committee. USP General Chapter <800>
4 Step Cleaning Process
 All areas and reusable equipment where HDs are 
handled must be deactivated/decontaminated & 
cleaned
Cleaning Step Purpose Example Agents
Deactivation Render compound inert or 
inactive
• Sodium hypochlorite or 
EPA registered oxidizer
• Peroxide formulations




Cleaning Remove organic and 
inorganic material
• Germicidal detergent
Disinfection Destroy microorganisms • Sterile alcohol and/or 
EPA-registered 
disinfectant
USP Compounding Expert Committee. USP General Chapter <800>
Deactivation & Decontamination
 Carefully selected agent
 Hazardous byproducts
 Respiratory effects
• Some solutions may require the addition of respiratory 
protection 
 Caustic damage to surfaces
• Sodium hypochlorite causes corrosion
 MUST be neutralized with sodium thiosulfate or by following 
with another agent (ex: sterile alcohol) to remove it
Deactivator Decontaminator
USP Compounding Expert Committee. USP General Chapter <800>
Cleaning & Disinfecting
 Cleaning
 Removal of contaminants and HD residue
 Detergents or solvents
 Disinfection
 Kills microorganisms
 Used after cleaning
 Sterile compounding areas
Cleaner & Disinfectant
USP Compounding Expert Committee. USP General Chapter <800>
Spills
 MUST be contained and cleaned immediately
 By qualified personnel with appropriate PPE
 Facility dependent processes 
 Must have a clear policy and checklist
• Document competence of personnel, circumstances 
and management of spills
 Spill kits
 Respirators (if too large for a spill kit)
USP Compounding Expert Committee. USP General Chapter <800>
Spill Kit Example
Oral Chemotherapy Handling and 
Disposal
Oral Chemotherapy
 Traditional oral chemotherapy agents available since 
1950s
 Prescriptions of oral chemotherapy are becoming 
more common
 Make up around 25% of the oncology market
 Convenient but not just any pill
 Still requires extra caution
Association of Community Cancer Centers. Oral chemotherapy: what your patients need to know
Oral Chemotherapy
https://www.dana-farber.org/chemotherapy/oral-chemotherapy/
Safe Handling at Home
 Principles of safe handling
 Keep in original container
 Storage
• Store in a cool, dry place and away from sunlight
• Safe space away from children and pets
 Wash hands before and after handling
 Do not crush, break or chew
 Stay consistent with administration
 Do not dispose in the toilet or in the garbage
 Incorporate these key items in your counseling
https://www.dana-farber.org/chemotherapy/oral-chemotherapy/
Wearing Gloves at Home
 Gloves help protect caregivers from absorbing 
chemotherapy through the skin
 Some package inserts recommend gloves to be used
 Should be worn any time chemotherapy is handled by 
someone other than the patient
 Patients do not need to wear gloves when taking 
their medication
 Washing hands thoroughly before and after handling will 




 Applied to the skin
 Cream, gel, or ointment
 Example: 5-fluorouracil
 Consider recommending the use of gloves when applying 
topical agents
Oral/Topical Chemotherapy Disposal
 Improper disposal pollutes the water and ground 
and is toxic to plants, animals and humans
 Only a few drug manufacturers provide instructions 
on oral chemotherapy disposal
 Celgene, the maker of lenalidomide, thalidomide, and 
pomalidomide provides patients with packaging material 
to return unused medications
Association of Community Cancer Centers. Oral chemotherapy: what your patients need to know
Oral/Topical Chemotherapy Disposal
 Most cities have a hazardous waste disposal policy 
that patients can follow
 Most fire/police stations and retail pharmacies will not
dispose of oral chemotherapy
 Different options for patients
 Contact dispensing pharmacy for disposal
 Hazardous waste pick up through state of Florida
 Drug take back site or program
Association of Community Cancer Centers. Oral chemotherapy: what your patients need to know
Oral/Topical Chemotherapy Disposal
 Drug take back site or program
 Patients can locate an authorized collection location 
in their area online
 https://apps2.deadiversion.usdoj.gov/pubdispsearch/sprin
g/main?execution=e1s1
Association of Community Cancer Centers. Oral chemotherapy: what your patients need to know
Oral/Topical Chemotherapy Disposal
https://apps2.deadiversion.usdoj.gov/pubdispsearch/spring/main?execution=e1s1
DEA National Drug Take-Back Day
 April 25, 2020
 Liquid medications and IV medications are not 
accepted
 Results of October 2019 
 Total Law Enforcement Participation: 4,896
 Total Collection Sites: 6,174
 Total Weight Collected: 882,919 lbs. (441.5 Tons)
https://www.oncolink.org/blogs/2019/10/tomorrow-is-national-prescription-drug-take-back%E2%80%8B-day/
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Florida State Board of Pharmacy Laws
 Effective: 08/19/2019
 64B16-27.797 The Standards of Practice for 
Compounding Sterile Products
 Beginning on October 1, 2014, all sterile compounding 
shall be performed in accordance with the minimum 
practice and quality standards of the following chapters of 
the United States Pharmacopeia (USP):
 (a) Chapter 797, Pharmaceutical Compounding-Sterile 
Preparations;
 (b) Chapter 71, Sterility Tests;
 (c) Chapter 85, Bacterial Endotoxins Test;
 (d) Chapter 731, Loss on Drying.
